vs
Side-by-side financial comparison of MEDIFAST INC (MED) and STEM, INC. (STEM). Click either name above to swap in a different company.
MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $47.1M, roughly 1.6× STEM, INC.). On growth, STEM, INC. posted the faster year-over-year revenue change (-15.6% vs -36.9%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs -34.4%).
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
MED vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $47.1M |
| Net Profit | — | $-16.0M |
| Gross Margin | 69.4% | 48.9% |
| Operating Margin | -10.4% | -17.7% |
| Net Margin | — | -33.9% |
| Revenue YoY | -36.9% | -15.6% |
| Net Profit YoY | — | 68.8% |
| EPS (diluted) | $-1.64 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $47.1M | ||
| Q3 25 | $89.4M | $38.2M | ||
| Q2 25 | $105.6M | $38.4M | ||
| Q1 25 | $115.7M | $32.5M | ||
| Q4 24 | $119.0M | $55.8M | ||
| Q3 24 | $140.2M | $29.3M | ||
| Q2 24 | $168.6M | $34.0M | ||
| Q1 24 | $174.7M | $25.5M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | $-2.3M | $-23.8M | ||
| Q2 25 | $2.5M | $202.5M | ||
| Q1 25 | $-772.0K | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $1.1M | $-148.3M | ||
| Q2 24 | $-8.2M | $-582.3M | ||
| Q1 24 | $8.3M | $-72.3M |
| Q4 25 | 69.4% | 48.9% | ||
| Q3 25 | 69.5% | 35.5% | ||
| Q2 25 | 72.6% | 33.4% | ||
| Q1 25 | 72.8% | 32.4% | ||
| Q4 24 | 74.1% | -4.4% | ||
| Q3 24 | 75.4% | 21.2% | ||
| Q2 24 | 73.2% | 27.6% | ||
| Q1 24 | 72.8% | -95.0% |
| Q4 25 | -10.4% | -17.7% | ||
| Q3 25 | -4.6% | -33.6% | ||
| Q2 25 | -1.0% | -34.8% | ||
| Q1 25 | -1.1% | -65.0% | ||
| Q4 24 | 0.6% | -84.4% | ||
| Q3 24 | 1.5% | -493.2% | ||
| Q2 24 | -4.7% | -1705.5% | ||
| Q1 24 | 4.5% | -267.0% |
| Q4 25 | — | -33.9% | ||
| Q3 25 | -2.5% | -62.2% | ||
| Q2 25 | 2.3% | 527.8% | ||
| Q1 25 | -0.7% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | 0.8% | -506.3% | ||
| Q2 24 | -4.8% | -1712.6% | ||
| Q1 24 | 4.8% | -283.9% |
| Q4 25 | $-1.64 | $-4.40 | ||
| Q3 25 | $-0.21 | $-2.84 | ||
| Q2 25 | $0.22 | $-1.79 | ||
| Q1 25 | $-0.07 | $-0.15 | ||
| Q4 24 | $0.08 | $-15.29 | ||
| Q3 24 | $0.10 | $-18.24 | ||
| Q2 24 | $-0.75 | $-71.81 | ||
| Q1 24 | $0.76 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $198.9M | $-249.4M |
| Total Assets | $248.0M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.3M | $48.9M | ||
| Q3 25 | $173.5M | $43.1M | ||
| Q2 25 | $162.7M | $40.8M | ||
| Q1 25 | $164.6M | $58.6M | ||
| Q4 24 | $162.3M | $56.3M | ||
| Q3 24 | $170.0M | $75.4M | ||
| Q2 24 | $163.5M | $89.6M | ||
| Q1 24 | $156.4M | $112.8M |
| Q4 25 | $198.9M | $-249.4M | ||
| Q3 25 | $214.7M | $-235.7M | ||
| Q2 25 | $216.0M | $-214.1M | ||
| Q1 25 | $211.0M | $-417.5M | ||
| Q4 24 | $210.1M | $-398.4M | ||
| Q3 24 | $207.3M | $-344.1M | ||
| Q2 24 | $205.3M | $-203.2M | ||
| Q1 24 | $211.0M | $371.6M |
| Q4 25 | $248.0M | $308.9M | ||
| Q3 25 | $268.2M | $362.6M | ||
| Q2 25 | $269.3M | $379.2M | ||
| Q1 25 | $280.0M | $405.1M | ||
| Q4 24 | $284.2M | $437.4M | ||
| Q3 24 | $291.2M | $537.8M | ||
| Q2 24 | $293.5M | $691.5M | ||
| Q1 24 | $302.8M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.3M | $8.2M |
| Free Cash FlowOCF − Capex | $-6.6M | — |
| FCF MarginFCF / Revenue | -8.8% | — |
| Capex IntensityCapex / Revenue | 1.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.3M | $8.2M | ||
| Q3 25 | $12.1M | $11.4M | ||
| Q2 25 | $-3.4M | $-21.3M | ||
| Q1 25 | $3.4M | $8.5M | ||
| Q4 24 | $-4.9M | $-14.7M | ||
| Q3 24 | $9.1M | $-9.4M | ||
| Q2 24 | $13.1M | $-11.9M | ||
| Q1 24 | $7.3M | $-621.0K |
| Q4 25 | $-6.6M | — | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $11.1M | — | ||
| Q1 24 | $5.4M | — |
| Q4 25 | -8.8% | — | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | -4.5% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | -6.1% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 3.1% | — |
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.36× | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
